New hope for kids with rare brain tumors: experimental drug enters human testing
NCT ID NCT07158710
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-stage trial tests an oral drug called HSK42360 in children aged 6 to 17 with recurrent malignant brain tumors that have a specific BRAF V600 mutation. The study aims to find the safest dose and check for side effects, while also looking at whether the drug can shrink tumors. About 159 children who have already tried standard treatments without success will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK42360 (oral drug)
- What this could lead to
- If successful, this could point toward a new treatment option for children with hard-to-treat BRAF-mutant brain tumors.
- What could go wrong
- This is a very early Phase 1 trial with only 159 participants. The main goal is safety, not proof of effectiveness, and the drug may not shrink tumors or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT BRAIN TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China
RECRUITINGBeijing, Beijing Municipality, 100070, China
-
Fudan University Affiliated Huashan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
-
The Third Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
-
The first affiliated hospital of fujian medical university
RECRUITINGFuzhou, Fujian, 350200, China
-
Xuanwu Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510280, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.